Insmed Incorporated (INSM) AI Stock Analysis

Insmed Incorporated is a biopharmaceutical company specializing in developing and commercializing therapies for patients with severe and uncommon diseases. Its commercial product ARIKAYCE is part of an antibacterial regimen for adult patients combating Mycobacterium avium complex lung disease. Insmed is also advancing Brensocatib, an oral dipeptidyl peptidase 1 inhibitor for bronchiectasis and neutrophil-mediated inflammatory conditions. Additionally, its pipeline features Treprostinil Palmitil Inhalation Powder, an inhalable formulation designed to treat pulmonary arterial hypertension and other rare pulmonary disorders. Headquartered in Bridgewater, New Jersey, the company was founded in 1988 and focuses on addressing unmet medical needs in underserved patient populations.

Annual revenue grew from $188.5M in FY2021 to $245.4M in FY2022, $305.2M in FY2023, $363.7M in FY2024, and $606.4M in FY2025, achieving a 5-year revenue CAGR of 29.8% from FY2020 to FY2025. Annual revenue growth accelerated to 66.7% in FY2025, supported by a gross margin of 79.4%. Operating margin for FY2025 was -194.0%, and net income stood at -$1.28B with EPS of -$6.41, as R&D expense reached $771.1M. Over the trailing twelve months, revenue reached $1.14B with quarterly revenue growth of 296.1% for the quarter ended June 30, 2026. TTM profit margin was -76.9% and TTM EPS was -$4.10.

As of June 30, 2026, Insmed held $1.16B in cash and short-term investments alongside total debt of $579.9M, yielding net cash of $580.4M. Shareholders' equity was $757.5M out of $2.10B in total assets. The company maintained liquidity with a current ratio of 3.72 and a debt-to-equity ratio of 0.77. In FY2025, operating cash flow was -$935.0M and free cash flow was -$967.6M, with capital expenditures of $32.6M. Furthermore, the company's share count increased 83.4% over 5 years.

At a share price of $96.27 as of October 16, 2026, Insmed had a market cap of $21.02B and enterprise value of $25.80B. The stock trades at a forward P/E of 97.1x, significantly higher than the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 18.5x compared to the peer median of 4.1x, with an EV-to-revenue ratio of 22.2x and a PEG of 1.09. Over the past year, the stock fell 41.0%, underperforming the 16.8% return of SPY, though its 5-year return of 263.4% outperformed SPY's 83.0%.

Wall Street analysts maintain 18 Strong Buy, 5 Buy, and 1 Hold ratings, with 0 Sell or Strong Sell recommendations. The mean price target of $197.00 represents a 104.6% premium over the last close of $96.27. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.80B and an EPS of -$1.59, representing an EPS growth estimate of 75.2%. For next fiscal year, 17 analysts project revenue of $2.91B and positive EPS of $0.80. The company beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for October 29, 2026.

This page is an AI-written research summary of Insmed Incorporated (INSM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: INSM income statement, INSM balance sheet, INSM key metrics, INSM analyst forecast, INSM chart. See the INSM stock overview for the latest quote and news.